Atlas Trials

A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

Clinical trial NCT07700966 · RECRUITING

Trial details

NCT number
NCT07700966
Sponsor
Abeona Therapeutics, Inc
Status
RECRUITING
Study type
OBSERVATIONAL
Recessive Dystrophic Epidermolysis Bullosa
Start date
2025-07-25
Primary completion
2045-04-01
Enrollment
250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.